Long-term treatment and prognostic factors of α1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: A pilot study comparing naftopidil and tamsulosin hydrochloride

Scandinavian Journal of Urology and Nephrology

Volumn 44, Issue 1, 2010, Pages 38-45

  Kawachi, Yoshio ^a   Sakurai, Toru ^a   Sugimura, Sosuke ^a   Iwata, Shinji ^a   Noto, Kensho ^a   Honda, Shin Ichi ^a   Maruyama, Osamu ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b Department of Urology   (Japan)

Author keywords

1 Blockers; BPH LUTS; Long term administration

Indexed keywords

NAFTOPIDIL; TAMSULOSIN;

ARTICLE; CONTROLLED STUDY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LONG TERM CARE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RESIDUAL VOLUME; TREATMENT FAILURE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PILOT PROJECTS; PIPERAZINES; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATISM; RETROSPECTIVE STUDIES; SULFONAMIDES; TIME FACTORS;

EID: 76749157453     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365590903335221     Document Type: Article

References (15)

1. AUA Practice Guidelines Committee. AUA Guideline on the management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530-547
2. Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel a1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human a1-adrenoceptors. Jpn J Pharmacol. 1999;79:447-454
3. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The longterm effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:237-298
4. De la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using alfa1-blockers for lower urinary tract symptoms. J Urol. 2002;167:1734-1739
5. Masumori N, Hashimoto J, Itoh N, Tsukamoto T. Shortterm efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand J Urol Nephrol. 2007;8:1-8.
6. Ikemoto I, Kiyota H, Ohishi Y, Abe K, Goto H, Kishimoto K, et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative randomized twodrug crossover study. Int J Urol. 2003;10:587-594
7. Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006;97:747-751
8. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int. 2005;96:581-586
9. Foster HE Jr, Yono M, Shin D, Takahashi W, Pouresmail M, Afiatpour P, et al. Effects of chronic administration of doxazosin on alpha1-adrenoceptors in the rat prostate. J Urol. 2004;172:2465-2470
10. Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, Kohri K, et al. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor- subtype-selective antagonist naftopidil in benign prostate hyperplasia patients. Prostate. 2007;67:1285-1292
11. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158: 481-487 (Pubitemid 27327692)
12. Emberton M, Elhilali M, Matzkin H, Harving N, van Moorselaar J, Hartung R, et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology. 2005;66:316-322
13. Cam K, Akman Y, Kayikci A, Senel F, Erol A. Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms. Int J Urol. 2003;10:582-586
14. Hong SJ, Ko WJ, Kim SI, Chung BH. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. Eur Urol. 2003;44:94-100.
15. de Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol. 2003;169:535-539